Neurodegenerations are diseases of the present and the future
DOI:
https://doi.org/10.12775/JEHS.2022.12.11.003Keywords
Neurodegenerations, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinocerebellar ataxia, spinal muscular ataxia, amyotrophic lateral sclerosis, prion diseaseAbstract
Neurodegenerations are diseases of the present and the future. As the human population grows, the number of people suffering from neurodegenerative diseases will increase. Neurodegenerations diseases are Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinocerebellar ataxia, spinal muscular ataxia), sporadic (amyotrophic lateral sclerosis) or infectious (prion disease). Nerve cells (neurons) can’t regenerate and therefore die under the influence of pathological factors. Neurodegenerations diseases can be serious or life-threatening. It depends on the type. Drags and treatments may help improve symptoms, relieve pain, and increase mobility.
References
Barber S.C., S. P. (2010). Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic. Free Radic. Biol.Med., 48: 629-641.
Bateman Randall J.B.R. (2007). Testing a test for Alzheimer disease. Neurology, 68.
Bates G., H. P. (2002). The epidemiology of Huntington’s disease. Huntington’s disease. Oxford University Press, New York, 159-197.
Bensimon G, D. A. (2004). The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf., 3: 525-34.
Braak H, D. T. (2012). Where, when, and in what form does sporadic Alzheimer's Disease begin? Curr Opin Neurol, 708–714.
Dementia in Europe Yearbook 2019 Estimating the prevalence of dementia in Europe. (2019).
Ferraiuolo L., K. J. (2011). Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol., 7: 616-630.
Han X. (2004). The role of apolipoprotein E in lipid metabolism in the central nervous system. Cell Mol Life Sci., 61:1896-1906.
Hoepken HH, G. S. (2008). Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol , 212: 307-313.
Hulstaert F., B. K. (1999). Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555-1562.
Ince P.G., C. B. (1991). Disease of movement and system degeneration. Motor neuron disease (amyotrophic lateral sclerosis). Greenfield’s Neuropat.
Louis E.D., M. S. (2015). Merritt Neurology.
Mckhann G., D. D. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task. Neurology 34, 939-944.
Mollenhauer B, C. V. (2008). Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol., 213: 315–325.
Morris J. (2003). Antecedent biomarkers in Alzheimer's disease. Alzforum, 11:7.
Nowacki P. (2019). Mechanisms underlying amyotrophic lateral sclerosis. Neurol Prakt., 1: 7-12.
P., N. (2019). Mechanisms underlying amyotrophic lateral sclerosis. Neurol Prakt., 1: 7-12.
Pringsheim T., W. K. (2012). The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov. Disord., 27: 1083-1089.
Reuter I. (2019). Choroba Parkinsona. Edra Urban & Partner.
Saniewska N., S. N. (2019). Wiedza pacjentów obciążonych rdzeniowym zanikiem mięsni (SMA) oraz ich opiekunów na temat choroby. Prymat.
Sawada H. (2017). Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother., 18: 735-8.
Scarmeas N., S. Y. (2009). Mediterranean diet and mild cognitive impairment. Arch. Neurol. , 66: 216-225.
Siddique N., S. T. (2001). Amyotrophic Lateral Sclerosis. National Library of Medicine.
Sławek J., S. W. (2013). Choroba Huntingtona — w 20. rocznicę odkrycia genu IT15; patogeneza, diagnostyka i leczenie. Pol. Przegl. Neurol, 9(3):85-95.
Stefanis L. (2012). Alpha-Synuclein in Parkinson's disease. Cold Spring Harb. Perspect. Med.
Von Campenhausen S., B. B. (2005). Prevalance and ncience of Parkinson’s disease in Europe . Neuropsychopharma-col, 15: 473-490.
Wei Z., X. L. (2018). Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis. Front. Mol. Neurosci.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ewelina Górska, Sylwia Bogdan, Ewa Gorodkiewicz, Adam Hermanowicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 644
Number of citations: 0
